Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 5/20 | 0.53 |
| ▸ | MMP2 | P08253 | 15/20 | 0.53 |
| ▸ | MMP9 | P14780 | 13/20 | 0.53 |
| ▸ | MMP13 | P45452 | 5/20 | 0.52 |
| ▸ | MMP8 | P22894 | 2/20 | 0.52 |
| ▸ | MMP3 | P08254 | 4/20 | 0.51 |
| ▸ | MMP1 | P03956 | 3/20 | 0.51 |
| ▸ | MMP7 | P09237 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6768748 | 0.91 | MMP2 (0.57) | MMP2MMP9MMP13MMP3MMP1 | |
| SCHEMBL6769986 | 0.90 | MMP2 (0.52) | MMP2MMP9MMP13MMP8MMP3 | |
| SCHEMBL7493406 | 0.90 | MMP2 (0.55) | ADAMTS4MMP2MMP9MMP13MMP8 | |
| SCHEMBL6769969 | 0.90 | MMP2 (0.55) | ADAMTS4MMP2MMP9MMP13MMP8 | |
| SCHEMBL7493868 | 0.90 | MMP2 (0.52) | MMP2MMP9MMP13MMP8MMP3 | |
| SCHEMBL8062219 | 0.87 | NPSR1 (0.49) | MMP2MMP9MMP13MMP8MMP3 | |
| SCHEMBL3611768 | 0.85 | SMN1; SMN2 (0.46) | — | |
| SCHEMBL8088247 | 0.85 | SMN1; SMN2 (0.46) | — | |
| SCHEMBL15943338 | 0.82 | MMP2 (0.75) | ADAMTS4MMP2MMP9MMP13MMP3 | |
| SCHEMBL7400420 | 0.79 | MMP2 (0.55) | ADAMTS4MMP2MMP9MMP13MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762198-B2 | SUCH AS 2-((4'-METHOXY-(1,1'-BIPHENYL)-4-YL)-SULFONYL)-AMINO-3-(2-PHENOXYMETHYL -(1,3)DIOXAN-2-YL)PROPIONIC ACID | THE PROCTER & GAMBLE COMPANY | 2004-07-13 | — | — | US | disclosed |
| US-20030225074-A1 | Dihetero-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-6566381-B1 | For therapy of arthritis, cancer, cardiovascular disorder, skin disorder, ocular disorder, inflammation and gum disease | THE PROCTER & GAMBLE COMPANY | 2003-05-20 | — | — | US | disclosed |
| EP-1165530-A2 | DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000051993-A2 | DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225074-A1 | Dihetero-substituted metalloprotease inhibitors | ADAM9, ADAM17, ADAM8 | ADAMTS4 32/4885MMP2 10/4885MMP9 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.